ccc_R08

Research use only, not for human use.

ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection.

ccc_R08 (0.3, 1.0, 3.2, 10, 32 μM; 5 days) significantly reduces the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA) in HepDES19 cells.ccc_R08 (0-100 μM) dose-dependently reduces the level of extracellular HBeAg from HepDES19 cells, with IC50 of ~0.1 μM.Western Blot Analysis Cell Line:HepDES19 cells Concentration:0.3, 1.0, 3.2, 10, 32 μM Incubation Time:5 days Result:Reduced the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA).

ccc_R08 (20 mg/kg; p.o.; twice per day for 2 weeks) clears cccDNA from the liver of HBVcircle mice.ccc_R08 (10, 15, 20, 30 mg/kg; p.o.; twice per day for 2 weeks) significantly decreases the serum level of pgRNA in a dose-dependent manner, and the reduction in pgRNA is quantitatively correlated with that in liver cccDNA at different doses.Animal Model:HBVcircle mouse model .Dosage:20 mg/kg Administration:Oral administration; twice per day for 2 weeks Result:Led to the clearance of cccDNA from HBVcircle mouse livers.Animal Model:HBVcircle mouse model .Dosage:10, 15, 20, 30 mg/kg Administration:Oral administration; twice per day for 42 days Result:Led to a sustained reduction in the serum levels of pgRNA.

——

Microbiology/Virology

HBV

HBV

——

——

2919019-72-8

414.84

C22H19ClO6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (241.06 mM; Ultrasonic )

O=C(O)C1CC(OCCOC=2C=CC(=CC2)C=3OC=4C(Cl)=CC=CC4C(=O)C3)C1

——

(-20℃)

With Ice Pack

≥ 2 years